MedVellum
MedVellum
Back to Library

Tachycardia

On This Page

Overview

Tachycardia

Quick Reference

Critical Alerts

  • Unstable tachycardia (hypotension, altered consciousness, ischemia, acute heart failure) requires immediate cardioversion
  • Wide complex tachycardia should be treated as VT until proven otherwise
  • Avoid AV nodal blockers in atrial fibrillation with WPW (can cause VF)
  • Polymorphic VT (Torsades de Pointes) requires IV magnesium, not amiodarone
  • Regular narrow complex tachycardia often responds to vagal maneuvers or adenosine

Key Diagnostics

  • 12-lead ECG (essential for classification)
  • Continuous cardiac monitoring
  • Electrolytes (K+, Mg2+, Ca2+)
  • Troponin if ischemia suspected
  • TSH for new-onset atrial fibrillation
  • Medication/toxicology screen if indicated

Emergency Treatments

  • Unstable: Synchronized cardioversion (50-200J biphasic)
  • Stable narrow regular: Vagal maneuvers → Adenosine 6mg → 12mg → 12mg
  • Stable narrow irregular (AF): Rate control (diltiazem, metoprolol)
  • Stable wide regular (VT): Amiodarone 150mg IV over 10 min
  • Torsades de Pointes: Magnesium 2g IV bolus, defibrillation if unstable

Definition

Tachycardia is defined as a heart rate greater than 100 beats per minute in adults. While sinus tachycardia is a physiologic response to various stimuli, pathological tachycardias arise from abnormal impulse generation or conduction and may be life-threatening.

Classification by Mechanism

Automaticity

  • Enhanced normal automaticity (sinus tachycardia)
  • Abnormal automaticity (ectopic atrial tachycardia)

Triggered Activity

  • Early afterdepolarizations (Torsades de Pointes)
  • Delayed afterdepolarizations (digitalis toxicity)

Re-entry

  • Macro-re-entry (atrial flutter, AVRT)
  • Micro-re-entry (AVNRT, VT)

Classification by QRS Width and Regularity

QRS WidthRegularIrregular
Narrow (<120ms)Sinus tach, SVT, atrial flutterAF, MAT, flutter with variable block
Wide (≥120ms)VT, SVT with aberrancy, paced rhythmAF with aberrancy, polymorphic VT, AF with WPW

Pathophysiology

Electrical Conduction System

Normal Conduction

  1. SA node → Atria
  2. AV node (delay)
  3. Bundle of His → Bundle branches
  4. Purkinje fibers → Ventricles

Re-entrant Mechanisms

Requirements for Re-entry

  1. Two functionally distinct pathways
  2. Unidirectional block in one pathway
  3. Slow conduction in alternate pathway
  4. Recovery of excitability in blocked pathway

Common Re-entrant Circuits

ArrhythmiaCircuit
AVNRTDual AV node pathways (slow/fast)
AVRTAccessory pathway (e.g., WPW)
Atrial flutterRight atrial macroreentrant
VTScar-related ventricular circuit

Wolff-Parkinson-White (WPW) Syndrome

Accessory Pathway Conduction

  • Bypass tract connects atria and ventricles
  • Delta wave on ECG (during sinus rhythm)
  • Orthodromic AVRT: Narrow complex (antegrade via AV node)
  • Antidromic AVRT: Wide complex (antegrade via accessory pathway)

Danger in AF with WPW

  • AV node blockers can promote accessory pathway conduction
  • Very rapid ventricular response
  • Can degenerate to VF

Torsades de Pointes

Mechanism

  • Triggered by early afterdepolarizations
  • Usually in setting of prolonged QT interval
  • Causes: QT-prolonging drugs, hypokalemia, hypomagnesemia, bradycardia

Clinical Presentation

Symptoms

Common Symptoms

SymptomFrequencyNotes
PalpitationsVery commonAwareness of rapid/irregular heartbeat
DyspneaCommonReduced cardiac output
Chest painCommonMay indicate ischemia
DizzinessCommonCerebral hypoperfusion
Syncope/near-syncopeLess commonIndicates hemodynamic compromise
PolyuriaClassic for SVTANP release from atrial stretch

Symptoms Suggesting Instability

Physical Examination

Vital Signs

Cardiac Examination

FindingSignificance
Regular vs irregular rhythmClassification
Cannon A waves in neckAV dissociation (VT)
Variable S1 intensityAV dissociation
New murmurMay indicate structural disease
S3/S4 gallopHeart failure

Signs of Instability

ECG Characteristics by Arrhythmia

Narrow Complex Tachycardias

ArrhythmiaRateRegularityP WavesKey Features
Sinus tachycardia100-150RegularUpright in IIGradual onset/offset
AVNRT150-250RegularHidden or pseudo r' (V1), pseudo S (II,III,aVF)Abrupt onset/offset
AVRT150-250RegularVisible after QRS (RP <PR)May see delta wave in sinus
Atrial flutter150 (~300/2)RegularSawtooth (II, III, aVF)2:1 block common
Atrial fibrillationVariesIrregularly irregularAbsentFibrillatory baseline
MATVariesIrregularly irregular≥3 P wave morphologiesCOPD, hypoxia
Ectopic atrial tach100-250RegularAbnormal morphologyOften automatic

Wide Complex Tachycardias

FeatureFavors VTFavors SVT with Aberrancy
AV dissociationStrong for VT-
Capture/fusion beatsDiagnostic for VT-
Very wide QRS (>60ms)VT-
Positive/negative concordance (precordial)VT-
Known prior MI or structural heart diseaseVT-
Prior BBB with same morphology-SVT with known BBB
Age >0More likely VT-

Brugada Criteria for VT

  1. Absence of RS in precordial leads → VT
  2. RS interval >100ms in any precordial lead → VT
  3. AV dissociation → VT
  4. Morphology criteria in V1/V2 and V6 → VT

Hypotension
Common presentation.
Altered mental status
Common presentation.
Ischemic chest pain
Common presentation.
Signs of heart failure
Common presentation.
Red Flags (Life-Threatening)

Signs of Hemodynamic Instability

Red FlagConcernAction
SBP <90 mmHgHypotensionImmediate cardioversion
Altered mental statusCerebral hypoperfusionCardioversion
Chest pain with ischemic ECG changesOngoing ischemiaCardioversion
Acute pulmonary edemaHeart failureCardioversion
Signs of shockHypoperfusionCardioversion

High-Risk Arrhythmias

ArrhythmiaRiskImmediate Action
Polymorphic VT/TorsadesDegeneration to VFMagnesium, defibrillation
Wide complex tachycardia with hemodynamic compromiseVTCardioversion
Very rapid AF (>00 bpm)May indicate WPWAvoid AV nodal blockers
Irregular wide complex tachycardiaAF with WPWProcainamide or cardioversion
Monomorphic VTSudden death riskAntiarrhythmics, cardioversion

Differential Diagnosis

Approach to Narrow Complex Tachycardia

Step 1: Regular or Irregular?

Regular NCT

  • Sinus tachycardia
  • AVNRT
  • AVRT (orthodromic)
  • Atrial flutter with fixed block
  • Ectopic atrial tachycardia

Irregular NCT

  • Atrial fibrillation
  • Atrial flutter with variable block
  • Multifocal atrial tachycardia
  • Sinus tachycardia with ectopy

Approach to Wide Complex Tachycardia

Assume VT until proven otherwise (75-80% of WCT is VT)

Differential

  1. Ventricular tachycardia (most common)
  2. SVT with aberrant conduction (LBBB, RBBB)
  3. SVT with pre-excitation (antidromic AVRT)
  4. Pacemaker-mediated tachycardia
  5. Hyperkalemia with sinus tachycardia

Secondary Causes of Sinus Tachycardia

CategoryExamples
PhysiologicalExercise, anxiety, pain
HypovolemiaDehydration, hemorrhage
AnemiaBlood loss, hemolysis
InfectionSepsis, fever
MetabolicHyperthyroidism, hypoglycemia
CardiacHeart failure, MI, PE, tamponade
ToxicologicalStimulants, anticholinergics, withdrawal
MedicationsBeta-agonists, caffeine, theophylline

Diagnostic Approach

Initial Assessment

ABCDE Approach

  1. Airway: Patent
  2. Breathing: Assess for pulmonary edema
  3. Circulation: Pulse quality, BP, perfusion
  4. Disability: Mental status
  5. Exposure: Signs of underlying cause

Key Questions

  • Stable or unstable?
  • Narrow or wide QRS?
  • Regular or irregular?

ECG Interpretation Algorithm

Tachycardia (&gt;100 bpm)
         ↓
QRS &lt;120ms (Narrow) or ≥120ms (Wide)?
         ↓
    [NARROW]                      [WIDE]
         ↓                              ↓
  Regular or Irregular?         Treat as VT until proven
         ↓                              ↓
[Regular]    [Irregular]        Cardiovert if unstable
    ↓              ↓               OR
Vagal → AF        MAT          Antiarrhythmics if stable
Adenosine  Flutter w/
           variable block

Laboratory Studies

TestPurpose
12-lead ECGArrhythmia classification
BMPK+, Mg2+, Ca2+, renal function
CBCAnemia, infection
TroponinIschemia, demand ischemia
TSHHyperthyroidism (new AF)
D-dimerPE (if suspected)
Drug levelsDigoxin, theophylline
ToxicologyIf stimulant/poisoning suspected

Imaging

  • Chest X-ray: Cardiomegaly, pulmonary edema
  • Echocardiography: Structural heart disease, EF, wall motion abnormalities
  • CT-PA: If PE suspected

Treatment

Unstable Tachycardia Algorithm

Patient Unstable (hypotension, AMS, ischemia, acute HF)?
                      ↓
                 [YES] → SYNCHRONIZED CARDIOVERSION
                      ↓
    Narrow Regular: 50-100J
    Narrow Irregular (AF): 120-200J biphasic
    Wide Regular: 100J (may need 200J)
    Wide Irregular (polymorphic VT): DEFIBRILLATION (unsync) 120-200J
                      ↓
    Consider sedation if patient conscious (etomidate, midazolam)
    Repeat at higher energy if needed

Stable Narrow Complex Regular Tachycardia

Step 1: Vagal Maneuvers

  • Valsalva maneuver (modified Valsalva more effective)
  • Carotid sinus massage (if no contraindications)
  • Ice water immersion (diving reflex)

Modified Valsalva Technique

  1. Patient blows into syringe for 15 seconds (generate 40mmHg)
  2. Immediately lay patient supine
  3. Raise legs to 45° for 15 seconds
  4. Return to semi-recumbent position

Step 2: Adenosine

First dose: 6mg rapid IV push (central preferred)
           Follow immediately with 20mL NS flush
Wait: 1-2 minutes
           ↓
Second dose: 12mg if no conversion
           ↓
Third dose: 12mg if still no conversion

Adenosine Notes

  • Very short half-life (~10 seconds)
  • Causes brief asystole/bradycardia (warn patient)
  • May cause flushing, chest tightness (reassure)
  • Use 3mg initially if central line or on dipyridamole
  • May need higher dose if on caffeine/theophylline

Step 3: If Adenosine Fails

DrugDoseNotes
Diltiazem15-20mg IV over 2 minMay repeat 20-25mg
Verapamil2.5-5mg IV over 2 minMay repeat 5-10mg
Metoprolol5mg IV, repeat q5min x3Caution in heart failure

Stable Narrow Complex Irregular Tachycardia (AF/Flutter)

Rate Control

DrugDoseNotes
Diltiazem15-20mg IV, then 5-15mg/hrFirst-line in most
Metoprolol5mg IV q5min x3Avoid in asthma, CHF
Digoxin0.5mg IV, then 0.25mg q6h x2Slow onset, HF ok
Amiodarone150mg IV over 10 minAF with HF/hypotension

Rhythm Control Considerations

  • <48 hours duration: May cardiovert without anticoagulation
  • >48 hours or unknown: TEE-guided cardioversion or anticoagulation x3 weeks then cardiovert
  • Pharmacological: Ibutilide, flecainide, propafenone, amiodarone

Wide Complex Tachycardia - Stable

Assume VT - Treat with:

Amiodarone: 150mg IV over 10 minutes
            May repeat 150mg in 10-15 min if needed
            Then 1mg/min infusion x6 hours, then 0.5mg/min x18 hours
            
OR

Procainamide: 20-50mg/min until:
              - Arrhythmia terminates
              - Hypotension
              - QRS widens &gt;50%
              - Total dose 17mg/kg
              Then 1-4mg/min maintenance
              
OR

Lidocaine: 1-1.5mg/kg IV bolus
           0.5-0.75mg/kg q5-10min (max 3mg/kg)
           Then 1-4mg/min infusion

Torsades de Pointes

Step 1: Magnesium sulfate 2g IV bolus over 1-2 min
        Follow with 1-2g/hr infusion

Step 2: If not converting/unstable: DEFIBRILLATION (not sync)

Step 3: Increase heart rate (shortens QT)
        - Isoproterenol infusion
        - Temporary overdrive pacing (100-120 bpm)

Step 4: Correct underlying cause
        - Stop QT-prolonging drugs
        - Correct K+ to 4.5-5 mEq/L
        - Correct Mg2+ to 2+ mEq/L

DO NOT USE: Amiodarone, sotalol, procainamide (prolong QT)

Atrial Fibrillation with WPW

Signs of Pre-excitation in AF

  • Very rapid rate (often >200 bpm)
  • Irregular wide complex
  • Varying QRS width (fusion beats)

Treatment

  • DO NOT USE: Adenosine, digoxin, CCBs, beta-blockers
  • USE: Procainamide or electrical cardioversion
  • If unstable: Immediate cardioversion

Disposition

Admission Criteria

ICU/Telemetry

  • Hemodynamic instability
  • Cardioversion performed
  • VT or high-risk arrhythmia
  • Significant structural heart disease
  • Ongoing ischemia
  • New heart failure

Observation/Telemetry

  • First episode requiring treatment
  • Symptomatic recurrence after treatment
  • Need for medication adjustment
  • Electrolyte abnormalities

Discharge Criteria

  • Stable rhythm (sinus or controlled AF)
  • Hemodynamically stable
  • No concerning symptoms
  • Electrolytes normal
  • Clear diagnosis with management plan
  • Follow-up arranged

Outpatient Referrals

ReferralIndication
CardiologyAll first-time arrhythmias needing treatment
ElectrophysiologyRecurrent SVT, WPW, VT for ablation
Emergency department returnRecurrent symptoms

Patient Education

Understanding Tachycardia

  • Tachycardia means fast heart rate
  • Many causes exist, from benign to serious
  • Treatment depends on the type and cause
  • Some conditions can be cured with ablation procedures

Vagal Maneuvers at Home

For patients with documented SVT:

  • Valsalva maneuver (bearing down)
  • Cold water on face
  • Only attempt if trained and safe to do so

Warning Signs to Return

  • Palpitations lasting >15-20 minutes
  • Associated chest pain
  • Shortness of breath
  • Dizziness or near-fainting
  • Fainting
  • Palpitations with exercise

Medication Adherence

  • Take rate control medications as prescribed
  • Do not miss anticoagulation doses if prescribed
  • Avoid excessive caffeine and alcohol
  • Report side effects promptly

Special Populations

Pediatric Considerations

Normal Heart Rates by Age

AgeNormal HRTachycardia Threshold
Infant100-160>80-190
1-3 years90-150>50
3-5 years80-140>40
>0 yearsSimilar to adult>00

SVT in Children

  • Most common arrhythmia in pediatrics
  • Often AVRT (accessory pathway)
  • Vagal maneuvers: Ice to face very effective
  • Adenosine dosing: 0.1mg/kg (max 6mg) then 0.2mg/kg (max 12mg)

Elderly Patients

  • Higher risk of falls with hypotension
  • More likely to have structural heart disease
  • More sensitive to medications
  • Caution with rate control agents

Pregnancy

Safe Medications

  • Adenosine: Safe
  • Beta-blockers: Generally safe (prefer metoprolol, labetalol)
  • Cardioversion: Safe at any gestational age

Avoid if Possible

  • Amiodarone (thyroid, neurological effects on fetus)
  • ACE inhibitors (if treating underlying cause)

Heart Failure

  • Avoid negative inotropes when possible
  • Amiodarone preferred for rate control
  • Digoxin remains option
  • Cardioversion may improve hemodynamics rapidly

Quality Metrics

Performance Indicators

MetricTarget
12-lead ECG within 10 min>5%
Time to cardioversion (unstable)<10 min
Documentation of QRS width100%
Electrolytes checked100%
Anticoagulation assessment for AF100%
Follow-up arranged100%

Documentation Requirements

  • 12-lead ECG findings
  • Classification of tachycardia
  • Hemodynamic status
  • Treatments given and response
  • Post-treatment rhythm
  • Anticoagulation plan (if AF)
  • Disposition rationale
  • Follow-up instructions

Key Clinical Pearls

Diagnostic Pearls

  1. Wide complex = VT until proven otherwise (80% are VT)
  2. Look for AV dissociation - cannon A waves, variable S1
  3. Regular at 150 bpm - think atrial flutter with 2:1 block
  4. Irregularly irregular without P waves = Atrial fibrillation
  5. Adenosine can be diagnostic even if it doesn't convert

Treatment Pearls

  1. Unstable = cardiovert - don't waste time with drugs
  2. Modified Valsalva has higher success than standard
  3. Adenosine needs fast push - arm with tourniquet, stopcock setup
  4. Avoid AV blockers in WPW with AF - can cause VF
  5. Magnesium is first-line for Torsades - not amiodarone

Disposition Pearls

  1. First VT = admission even if terminated
  2. Recurrent SVT may benefit from ablation - refer to EP
  3. New AF needs stroke risk assessment (CHA2DS2-VASc)
  4. Ensure electrolytes normalized before discharge
  5. Follow-up with cardiology for all arrhythmias requiring treatment

References
  1. January CT, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019.
  2. Al-Khatib SM, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation. 2018.
  3. Page RL, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation. 2016.
  4. Brugada J, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. Eur Heart J. 2020.
  5. Appelboam A, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of SVT (REVERT): a randomised controlled trial. Lancet. 2015.
  6. Link MS, et al. Part 7: Adult Advanced Cardiovascular Life Support. 2015 AHA Guidelines Update. Circulation. 2015.

Version History
VersionDateChanges
1.02025-01-15Initial comprehensive version with 14-section template

At a Glance

EvidenceStandard
Last UpdatedRecently

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines